---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-011178"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2025-04-07T23:59:59+00:00"
generated_at: "2026-05-23T19:21:23.414465+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports positive Phase 2b extension data for neflamapimod in DLB

## Summary
- Neflamapimod slowed clinical progression on CDR-SB vs old capsules (p<0.001) and vs placebo (p=0.003) over 16 weeks.
- Mean CDR-SB improvement of 0.73 points with new capsules vs old; 40% relative reduction in clinically meaningful worsening.
- Falls incidence reduced to 4% with new capsules vs 15.2% with old (p=0.025) in patients without AD co-pathology.
- Improvement also seen on ADCS-CGIC (p=0.035 vs old capsules) and cognitive/fluctuation endpoints.
- Company expects to complete full 32-week extension and engage FDA for Phase 3 plans later in 2025.

## SEC filing metadata
- accession: 0001437749-25-011178
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2025-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774925011178/0001437749-25-011178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774925011178/crvo20250407_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-011178
- JSON: https://secwatch.observer/filing/0001437749-25-011178.json
- Plain text: https://secwatch.observer/filing/0001437749-25-011178.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.